Eli Lilly And Co (NYSE:LLY) Shares Sold by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. cut its stake in Eli Lilly And Co (NYSE:LLY) by 1.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,764 shares of the company’s stock after selling 100 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Eli Lilly And Co were worth $971,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Trust Department MB Financial Bank N A lifted its stake in Eli Lilly And Co by 54.7% in the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after buying an additional 82 shares in the last quarter. Wealthquest Corp lifted its stake in Eli Lilly And Co by 1.5% in the 1st quarter. Wealthquest Corp now owns 6,307 shares of the company’s stock valued at $818,000 after buying an additional 94 shares in the last quarter. Lourd Capital LLC lifted its stake in Eli Lilly And Co by 2.7% in the 2nd quarter. Lourd Capital LLC now owns 3,723 shares of the company’s stock valued at $412,000 after buying an additional 97 shares in the last quarter. Meridian Wealth Advisors LLC lifted its stake in Eli Lilly And Co by 6.1% in the 1st quarter. Meridian Wealth Advisors LLC now owns 1,746 shares of the company’s stock valued at $227,000 after buying an additional 100 shares in the last quarter. Finally, Webster Bank N. A. lifted its stake in Eli Lilly And Co by 5.6% in the 2nd quarter. Webster Bank N. A. now owns 1,900 shares of the company’s stock valued at $210,000 after buying an additional 100 shares in the last quarter. 79.50% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have weighed in on LLY. Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a research note on Tuesday, April 23rd. TheStreet lowered shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a research note on Thursday, May 9th. Goldman Sachs Group began coverage on shares of Eli Lilly And Co in a research note on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Guggenheim lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price on the stock. in a research note on Thursday, April 11th. Finally, ValuEngine lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $123.49.

LLY traded up $1.91 during trading on Friday, reaching $112.42. The company’s stock had a trading volume of 4,477,611 shares, compared to its average volume of 3,834,467. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. The stock has a fifty day simple moving average of $111.04. Eli Lilly And Co has a 1 year low of $98.88 and a 1 year high of $132.13. The company has a market capitalization of $105.77 billion, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 1.91 and a beta of 0.19.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.45 by $0.05. The firm had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 58.65%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.48 EPS. On average, equities analysts expect that Eli Lilly And Co will post 5.72 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.29%. The ex-dividend date is Wednesday, August 14th. Eli Lilly And Co’s payout ratio is presently 46.49%.

In other news, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Joshua L. Smiley purchased 426 shares of Eli Lilly And Co stock in a transaction dated Wednesday, June 5th. The shares were purchased at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the transaction, the chief financial officer now owns 30,410 shares in the company, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is currently owned by insiders.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: How to build a Fibonacci channel

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.